{
    "clinical_study": {
        "@rank": "115953", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat."
            }, 
            {
                "arm_group_label": "AmnioFix", 
                "arm_group_type": "Experimental", 
                "description": "Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic\n      membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic\n      prostatectomies."
        }, 
        "brief_title": "Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy", 
        "condition": "Pudendal Nerve", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ages 45-70\n\n          2. Clinically localized prostate cancer with Gleason score 6 or 7\n\n          3. SHIM Score greater than or equal to 16 in the absence of medication\n\n          4. Feasibility to perform unilateral or bilateral nerve sparing RALP\n\n        Exclusion Criteria:\n\n          1. Clinically locally advanced cancer and/or with Gleason score 8 or 9.\n\n          2. Difficulty performing nerve sparing RALP.\n\n          3. Prior surgery at the site.\n\n          4. Site exhibits clinical signs and symptoms of infection.\n\n          5. SHIM score at screening <16.\n\n          6. Current use of anticoagulant medication including Coumadin, Plavix, etc.\n\n          7. Has had \"salvage prostatectomy\" - patients who failed prior therapies including\n             external radiation therapy, cryotherapy, etc.\n\n          8. Has prior radiation therapy treatment at the site.\n\n          9. Prior hormonal therapy such as Lupron or oral anti-androgens.\n\n         10. Non-mobile, i.e. not ambulatory or bed ridden.\n\n         11. The presence of comorbidities that can be confused with or can exacerbate the\n             condition including:\n\n               1. diabetes\n\n               2. advanced atherosclerotic vascular disease\n\n         12. Patients with a history of more than two weeks treatment with immuno-suppressants\n             (including systemic corticosteroids), cytotoxic chemotherapy within one month prior\n             to initial screening, or who receive such medications during the screening period, or\n             who are anticipated to require such medications during the course of the study.\n\n         13. Patients on any investigational drug(s) or therapeutic device(s) within 30 days\n             preceding screening.\n\n         14. Unable to comply with penile rehabilitation.\n\n         15. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.\n\n         16. Patients who are unable to understand the aims and objectives of the trial.\n\n         17. Presence of any condition(s) which seriously compromises the subject's ability to\n             complete this study, or has a known history of poor adherence with medical treatment.\n\n         18. Currently taking medications which could affect graft incorporation (supervising\n             physician's discretion).\n\n         19. Allergic to gentamicin and/or streptomycin.\n\n         20. Damage to neurovascular bundles during surgery."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832168", 
            "org_study_id": "AFRALP001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Control", 
                    "AmnioFix"
                ], 
                "description": "Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique", 
                "intervention_name": "Robotic Assisted Laparoscopic Prostatectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Application of Surgicel\u00ae SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.", 
                "intervention_name": "Application of Absorbable Hemostat", 
                "intervention_type": "Other", 
                "other_name": "Surgicel\u00ae SNoW"
            }, 
            {
                "arm_group_label": "AmnioFix", 
                "description": "Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.", 
                "intervention_name": "Application of dehydrated human amniotic membrane", 
                "intervention_type": "Other", 
                "other_name": "AmnioFix"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33176"
                }, 
                "name": "Jackson South Urology Center of Excellence"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.", 
        "overall_official": {
            "affiliation": "Jackson South Urology Center of Excellence", 
            "last_name": "Sanjay Razdan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832168"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to return of erectile function.", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Pain scores.", 
                "time_frame": "10 days, 4 weeks, 3 months, and 6 months"
            }
        ], 
        "source": "MiMedx Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MiMedx Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}